The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Vertex Drug Promising in Hepatitis C Patients With HIV

March 7, 2011

Substantially more HIV/hepatitis C virus co-infected patients taking the investigational HCV drug telaprevir achieved a rapid viral response (RVR) than those taking standard therapy alone, researchers reported at the 18th Conference on Retroviruses and Opportunistic Infections in Boston. RVR, defined as undetectable HCV after four weeks of treatment, can be an early indicator of eventually attaining a sustained viral response (SVR).


In previous trials, telaprevir has improved rates of SVR when used in combination with pegylated interferon and ribavirin. Vertex Pharmaceuticals Inc.'s drug is awaiting approval by the Food and Drug Administration.

The small, mid-stage trial presented at the conference involved 60 hepatitis C patients co-infected with HIV who were either taking antiretroviral therapy or not (non-ARV).

At four weeks, 70 percent taking combination HCV therapy with telaprevir achieved RVR, compared with just 5 percent on standard HCV therapy. Of patients taking Atripla, 75 percent achieved RVR on the telaprevir combination, versus one patient (12.5 percent) in the control arm. Of HIV patients taking Reyataz, 64 percent had RVR and no one did in the control arm. In non-ARV patients, 71 percent in the telaprevir group achieved RVR compared with none on standard therapy.

SVR data are expected next year, Vertex said.

Back to other news for March 2011

Adapted from:
03.02.2011; Bill Berkrot

  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
See Also
More From the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
More News and Research on Incivek (Telaprevir)

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: